KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and activity of MEN2312 in participants with hematological malignancies.
Epistemonikos ID: a672639f056b2124f062f53e51eb5531fc7ca393
First added on: Oct 15, 2026